Vertex Pharmaceuticals shares jump 6.86% after-hours after Morgan Stanley upgrades to Overweight with $516 price target on kidney drug pipeline.

Vertex Pharmaceuticals surged 6.86% in after-hours trading following Morgan Stanley's upgrade of its rating to "Overweight" from "Equal-Weight," accompanied by a raised price target to $516 from $438. The upgrade highlighted optimism around Vertex's kidney drug pipeline, particularly candidates Pove and Inaxaplin, with Phase 3 clinical trial data expected in 2026. This analyst action directly aligned with the stock's significant move, underscoring renewed confidence in the company's long-term prospects.